viewKibo Energy PLC

Kibo Energy to raise £1.5mln as it focuses on sustainable energy

Kibo has recently pivoted its model to focus on sustainable electricity

Kibo Energy PLC -
£1mln of fund raise is underwritten

Kibo Energy PLC (LON:KIBO) is to raise a minimum of £1.5mln through a placing at 0.45 pence per share to fund its work on power projects in southern Africa and the UK.

Of the total, £1mln is being underwritten with directors and management subscribing for a chunk of the other £500,000.

Kibo has recently pivoted its model to focus on sustainable electricity and aims to become a significant energy solutions provider in Africa.

Louis Coetzee, chief executive, says the plan for Kibo is to:

  • Guarantee long term sustainability and affordability in electricity supply;
  • Act as key catalyst for socio-economic development priorities in the various project jurisdictions; and
  • Give priority to implement energy solutions and strategies that will ensure the lowest possible environmental impact.

“To enable and execute this strategy, within the space of 18 months, we built a well-diversified portfolio, and concurrently developed it to bankable feasibility level, except for the MCIPP, which is at feasibility level.

“2019, in turn, delivered the first key successes towards the execution of our corporate strategy; the first HoT power purchase agreements and HoT definitive coal supply agreements across various projects were entered into and others are in an advanced stage of negotiation.”

Quick facts: Kibo Energy PLC

Price: 0.6225 GBX

Market: LSE
Market Cap: £7.83 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Faron Pharma CEO confident as he looks ahead to new Traumakine study

Faron Pharmaceuticals Oy (LON:FARN) (FIRSTNORTH:FARON) CEO Dr Markku Jalkanen caught up with Proactive London's Andrew Scott soon after announcing they've amended the protocol for a second phase III study of its drug for acute respiratory distress syndrome (ARDS). The tweak's in response to...

3 hours, 22 minutes ago

2 min read